ɪɾ ɪz nˌɑːt nˈoʊn wˈɛðɚ ðɪs sᵻlɪktˈɪvᵻɾi fɚðɪ ˈɛm θɹˈiː ɹᵻsˈɛptɚ tɹænslˈeɪts ˌɪntʊ ˌɛni klˈɪnɪkəl ɐdvˈæntɪdʒ wɛn tɹˈiːɾɪŋ sˈɪmptəmz ʌv ˌoʊvɚɹˈæktɪv blˈædɚ sˈɪndɹoʊm.
It is not known whether this selectivity for the M3 receptor translates into any clinical advantage when treating symptoms of overactive bladder syndrome.